Published in Cancer Vaccine Week, November 28th, 2005
According to a study from Germany, "Vaccine therapy of prostate cancer has been increasingly studied in trials over the past few years. The different vaccine techniques are quite variable and are predominantly used in patients with advanced hormone-refractory prostate cancer. In this review, vaccine techniques using tumor cells, dendritic cells, or poxvirus are analyzed. For theses approaches phase-III trials are being planned, have been initiated or are already completed."
"Many trials demonstrate the efficacy with regard to endpoints such as...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Vaccine Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.